Answers are grounded in this paper and cite their sources.
Demonstrates anti-obesity effects of isoliquiritigenin in rats, indicating potential for metabolic disorder treatment.
Isoliquiritigenin (ISL), a chalcone flavonoid derived from Glycyrrhiza uralensis (licorice), has garnered significant attention for its potential to treat chronic and metabolic disorders due to its antioxidant and anti-inflammatory effects (1,2,3) . Recent research underscores ISL’s effectiveness in mitigating metabolic disturbances, including obesity, insulin resistance (IR), and non-alcoholic fatty liver disease (NAFLD) (4) . However, the anti-obesity effects of ISL are still not understood. This study investigated the effects of ISL on adiposity in Wistar rats fed a high-fat diet (HFD), positing that ISL mitigates adiposity by inhibiting adipogenesis and promoting lipolysis via AMPK activation. Adult male Wistar rats were divided into six groups (n=8 each): Control (vehicle), Control + ISL (40 mg/kg), HFD (vehicle), HFD + ISL (20 mg/kg), HFD + ISL (40 mg/kg), and HFD + ISL (40 mg/kg) + Dorsomorphin (0.2 mg/kg; an AMPK blocker) for 12 weeks. All treatments were given orally by gavage. Dose was optimized based on our preliminary studies. In addition, we have previously shown that oral treatment with 30 mg/kg of ISL attenuates non-alcoholic fatty liver disease in HFD-fed animals by activating AMPK (Yahya et al., 2024). Other authors also showed that oral treatment with ISL at 10, 20, and 40 mg/kg effectively alleviated hyperglycemia and IR type-2 diabetes mellitus by activating AMPK (T2DM) rat model (5) . In a dose-dependent manner, ISL (thrice a week) significantly attenuated the increase in body weight and adipocyte size, improving glucose and insulin tolerance, HbA1c, and HOMA-IR without affecting food intake in HFD rats. Particularly, the higher dose of ISL (40 mg/kg) significantly increased the phosphorylation of AMPK (+193.3%), resulting in a p-AMPK/AMPK activity ratio increase of 191.0% in the white adipose (WAT) tissue of HFD rats. This also reduced body weight (24.6%), weight gain (28.7), fat deposit weight (-39.2% %), HOMA-IR (-67.62%), and serum triglycerides (-62.4%), cholesterol (56.7%), IL-6 (-66.1%), and TNF-α (-79.5%) in these HFD rats. It also increased p-ACC levels (+86.7%), Nrf2 mRNA Nrf2 (+392.7%), and PPARα mRNA (+255.0%), as well as the levels of HSL (+149.7%) and ATGL (139.62%). ISL (40 mg/kg) also decreased WAT levels of IL-6 (-57.86%), TNF-α (-74.96%), mRNA of SREBP1 (-38/8%), FAS (-50%) & NF-kB (58.8%), and levels of PLIN1 (-50.1) in these HFD rats. Dorsomorphin treatment reversed these effects in ISL + HFD rats. In conclusion, ISL demonstrates potent anti-obesity effects in HFD-induced rats through AMPK activation.
No takes yet. Share an insight, caveat, or question.
Mahmoud Alkhateeb (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: